Herbal medicine Ampucare for non-healing wounds 100% effective: Venus Remedies

Indian firm Venus Remedies has developed a herbal drug Ampucare to treat non-healing wounds.

Ampucare is a synergistic concentrate of aqueous and extracts of poly herbal ingredients.

The medicine has been used in over 500,000 cases with near 100 per cent effectiveness in treating non healing wounds from a variety of sources including; diabetic ulcers, amputee candidates (gangrene related), bedsores of varying levels and massive burn issues, Venus Remedies stated in a press release.

Venus is already marketing this product in the name of Ampucare and Septilock in India and some African and CIS countries.

Ampucare/Septilock not only possess strong antibacterial, anti- fungal properties but is also a pain killer, prevents inflammation, improves blood flow, provides tissue nutrition and promotes angiogenesis and faster granulation, thus resulting in complete wound healing.

Ampucare also reduced treatment time and thus helps in cutting down hospitalization time which ultimately lead to reduction in therapy cost.

The Chandigarh-based Venus Remedies Ltd announced that it would get assistance from the US-based Lockheed Martin Foundation and the University of Texas to launch Ampucare in the US market.

The assistance will be provided to Venus for having won the best innovation award under the India Innovation Growth Program 2010 organized by FICCI, Department of Science and Technology, Government of India, Lockheed Martin Corporation, IC2 Institute at the University of Texas and Indo-US Science & Technology Forum.

Venus Remedies was selected among a list of 394 applicants that comprised of varied sectors including aeronautics, medical/life sciences, agriculture, biotechnology, chemistry, communications, computing defence, among others.

In US, the industry is always on the look out for a solution for non healing wounds for illnesses like amputation due to diabetic foot ulcers (DFU) and severe burn injuries.
Many governmental agencies are now investing directly into wound technologies including US military. Ampucare has potential to prevent amputation in diabetic foot ulcer patients, Venus officials stated.

More than 40,000 leg amputations have been reported per year in India alone. There is an estimated 1.7 million people in US living with an amputation and approximately 135,000 new amputations yearly. In UK 5,000 people have an amputation/ year, that is, 100 people every week.

Ampucare is under patent protection in India and 50 other countries including US, China, Japan, 37 countries of EU, Canada, Mexico, Brazil, Russia, UAE, Vietnam, Korea, South Africa, Australia and New Zealand.

Globally, the wound care market is an estimated $11 billion dollar market of which 56 per cent is devoted to advanced wound care technology. In the US, the wound care market accounts for $2.6 billion in annual spending.

Market growth typically follows worldwide population growth patterns and is currently estimated to grow by 12 per cent per year. Some of the industry leaders in US wound care market include 3M, Johnson & Johnson, and Smith & Nephew.